We are using cookies to implement functions like login, shopping cart or language selection for this website. Furthermore we use Google Analytics to create anonymized statistical reports of the usage which creates Cookies too. You will find more information in our privacy policy.
OK, I agree I do not want Google Analytics-Cookies
Quintessence International



Forgotten password?


Quintessence Int 39 (2008), No. 8     16. July 2008
Quintessence Int 39 (2008), No. 8  (16.07.2008)

Page 673-678, PubMed:19107254

Oral effects of nonmyeloablative stem cell transplantation: A prospective observational study
Elad, Sharon / Shapira, Michael Y. / McNeal, Sandre / Or, Reuven / Garfunkel, Adi A. / Hirschhorn, Ariel / Bitan, Menachem / Resnick, Igor / Gesundheit, Benjamin / Barasch, Andrei
Objective: Nonmyeloablative stem cell transplantation (NST) is a relatively new type of hematopoietic stem cell transplantation (HSCT) that has gained wider use in the last decade. Oral effects of NST have not been described. The goal of the study was to evaluate the oral mucosal effects, including oral acute graft versus host disease (aGVHD), in patients undergoing NST in comparison to patients undergoing myeloablative HSCT.
Method and Materials: This prospective, longitudinal pilot study included 34 consecutive patients undergoing HSCT. Demographic data were collected. Patients were evaluated every 2 weeks between baseline and day 100 posttransplantation. Statistical methods included univariate and multivariable regression analyses (level of significance, P < .05).
Results: Patients undergoing NST had significantly less oral aGVHD (P = .032, OR = 0.11, CI: 0.02-0.83). Systemic aGVHD-related lesions were common in all patients. The prevalence of opportunistic oral infections was not statistically different between the NST and ablative groups (P = .94).
Conclusions: In this pilot study, cancer patients treated with NST had a lower incidence of oral aGVHD than those receiving myeloablative HSCT. The incidence of other oral soft tissue lesions, including opportunistic infections, was not affected by the type of HSCT.

Keywords: GVHD, hematopoietic stem cell transplantation, infection, myeloablative, oral